Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Murin

Showing results (221-230 of 315) with videos related to

Pageof 32
Sort By:
Chest|August 5, 2021
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Chest|August 5, 2021
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
Multisociety task force recommendations of competencies in Pulmonary and Critical Care MedicineJohn D Buckley, Doreen J Addrizzo-Harris, Alison S Clay, et al.
Circulation|November 23, 2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Harvey D White, Philip E G Aylward, Zhen Huang, et al.
Journal of Biotechnology|March 17, 2021
Biocompatibility of a nanocomposite based on Aerosil 380 and carboxylated fullerene C<sub>60</sub>[C(COOH)<sub>2</sub>]<sub>3</sub>Vladimir V Sharoyko, Gleb O Iurev, Viktor N Postnov, et al.
Cell|February 28, 2015
Mechanism of human antibody-mediated neutralization of Marburg virusAndrew I Flyak, Philipp A Ilinykh, Charles D Murin, et al.
Cell Reports|April 14, 2021
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodiesCharles D Murin, Pavlo Gilchuk, Philipp A Ilinykh, et al.
BMC Medicine|May 26, 2020
Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensusSusan Young, Jack Hollingdale, Michael Absoud, et al.
European Journal of Heart Failure|May 28, 2019
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real worldChris J Kapelios, Mitja Lainscak, Gianluigi Savarese, et al.
The Journal of Physical Chemistry Letters|September 3, 2025
Physicochemical Properties of a Water-Soluble Adduct of C<sub>60</sub> with l-Cysteine for Biomedical ApplicationsKonstantin N Semenov, Ali Mlhem, Alexander V Akentiev, et al.
Pageof 32

Showing results (221-230 of 315) with videos related to

Sort By:
Pageof 32
Chest|August 5, 2021
Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
Chest|August 5, 2021
Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel ReportScott M Stevens, Scott C Woller, Lisa Baumann Kreuziger, et al.
American Journal of Respiratory and Critical Care Medicine|August 8, 2009
Multisociety task force recommendations of competencies in Pulmonary and Critical Care MedicineJohn D Buckley, Doreen J Addrizzo-Harris, Alison S Clay, et al.
Circulation|November 23, 2005
Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Harvey D White, Philip E G Aylward, Zhen Huang, et al.
Journal of Biotechnology|March 17, 2021
Biocompatibility of a nanocomposite based on Aerosil 380 and carboxylated fullerene C<sub>60</sub>[C(COOH)<sub>2</sub>]<sub>3</sub>Vladimir V Sharoyko, Gleb O Iurev, Viktor N Postnov, et al.
Cell|February 28, 2015
Mechanism of human antibody-mediated neutralization of Marburg virusAndrew I Flyak, Philipp A Ilinykh, Charles D Murin, et al.
Cell Reports|April 14, 2021
Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodiesCharles D Murin, Pavlo Gilchuk, Philipp A Ilinykh, et al.
BMC Medicine|May 26, 2020
Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensusSusan Young, Jack Hollingdale, Michael Absoud, et al.
European Journal of Heart Failure|May 28, 2019
Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real worldChris J Kapelios, Mitja Lainscak, Gianluigi Savarese, et al.
The Journal of Physical Chemistry Letters|September 3, 2025
Physicochemical Properties of a Water-Soluble Adduct of C<sub>60</sub> with l-Cysteine for Biomedical ApplicationsKonstantin N Semenov, Ali Mlhem, Alexander V Akentiev, et al.
Pageof 32